The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing
Open accessAbstract
Endosomal escape remains a fundamental barrier hindering the advancement of nucleic acid therapeutics. Taking inspiration from natural phospholipids that comprise biological membranes, we report the combinatorial synthesis of multi-tailed ionizable phospholipids (iPhos) capable of delivering messenger RNA or mRNA/single-guide RNA for gene editing in vivo. Optimized iPhos lipids are composed of one pH-switchable zwitterion and three hydrophobic tails, which adopt a cone shape in endosomal acidic environments to facilitate membrane hexagonal transformation and subsequent cargo release from endosomes. Structure-activity relationships reveal that iPhos chemical structure can control in vivo efficacy and organ selectivity. iPhos lipids synergistically function with various helper lipids to formulate multi-component lipid nanoparticles (called iPLNPs) for selective organ targeting. Zwitterionic, ionizable cationic and permanently cationic helper lipids enable tissue-selective mRNA delivery and CRISPR-Cas9 gene editing in spleen, liver and lungs (respectively) following intravenous administration. This rational design of functional phospholipids demonstrates substantial value for gene editing research and therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Organ selectivity can also be achieved by adjusting the proportions of lipid components, for example, to design spleen-targeted mRNA vaccines26,27 or lung-targeted genome editing delivery systems114,134.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
In the citing paper
“For example, alteration of the alkyl length of a lipid results in selective accumulation of lipid nanoparticle–mRNA formulations in the liver or spleen114.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Membrane lipids: where they are and how they behave
van Meer, G., Voelker, D. R., & Feigenson, G. W. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2330 · Cited by 7,157
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Self-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Cited by
Sorted by citations
Items 101–200 of 652
Cao, Y., He, Z., Chen, Q., He, X., Su, L., Yu, W., Zhang, M., Yang, H., Huang, X., & Li, J. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01784 · Cited by 73
Paunovska, K., Sanchez, A. J. D. S., Lokugamage, M. P., Loughrey, D., Echeverri, E. S., Cristian, A., Hatit, M. Z. C., Santangelo, P. J., Zhao, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03741 · Cited by 78
Walther, J., Porenta, D., Wilbie, D., Seinen, C. W., Benne, N., Yang, Q., de Jong, O. G., Lei, Z., & Mastrobattista, E. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114207 · Cited by 80
Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond
Lin, Y., Cheng, Q., & Wei, T. (2023) · Biophysics Reports · doi:10.52601/bpr.2023.230022 · Cited by 77
“While tremendous efforts, such as developing novel lipid molecules (Liu et al. 2021) and optimizing internal ratios of lipid components (Cheng et al. 2018), have been made to improve the potency of LNPs, achieving efficient nucleic acid delivery to specific organs or cell types still presents a…”
BackgroundSelf-citationKim, S., Jeon, J. H., Kim, M., Lee, Y., Hwang, Y.-H., Park, M., Li, C. H., Lee, T., Lee, J.-A., Kim, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51411-9 · Cited by 78
“Target organ and cell types for mRNA delivery can differ according to the chemical properties of the nanoparticles used, representing a major research interest in developing LNP-based drugs 25,45 – 47 .”
Rational strategies for improving the efficiency of design and discovery of nanomedicines
Shan, X., Cai, Y., Zhu, B., Zhou, L., Sun, X., Xu, X., Yin, Q., Wang, D., & Li, Y. (2024) · Nature Communications · doi:10.1038/s41467-024-54265-3 · Cited by 81
“Inanother study, modularized synthesis of diverse lipids (572 kinds) was ef fi - ciently achieved via ring-opening reactions between alkylated dioxa-phospholaneoxidemoleculeamines 15 .”
CircRNA—Protein Interactions in Muscle Development and Diseases
Zheng, S., Zhang, X., Odame, E., Xu, X., Chen, Y., Ye, J., Zhou, H., Dai, D., Kyei, B., Zhan, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063262 · Cited by 72
Sago, C. D., Lokugamage, M. P., Loughrey, D., Lindsay, K. E., Hincapie, R., Krupczak, B. R., Kalathoor, S., Sato, M., Echeverri, E. S., Fitzgerald, J. P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00847-9 · Cited by 75
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 74
“sive factor in releasing mRNAs in the cytoplasm through ionization.(153,154) Therefore, LNPs have been widely utilized as the vehicle for mRNA drugs.”
MethodIn vivo fate and intracellular trafficking of vaccine delivery systems
Lee, J., Kim, D., Byun, J., Wu, Y., Park, J.-W., & Oh, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114325 · Cited by 72
“For example, a zwitterion ionizable lipid with one ionizable amine and phosphate groups in three hydrophobic tails, can transition to a hexagonal shape and thereby enhance the escape of cargo from endosomes via membrane destabilization [162].”
Zhang, R., Shao, S., Piao, Y., Xiang, J., Wei, X., Zhang, Z., Zhou, Z., Tang, J., Qiu, N., Xu, X., et al. (2023) · Advanced Materials · doi:10.1002/adma.202303614 · Cited by 72
He, Z., Le, Z., Shi, Y., Liu, L., Liu, Z., & Chen, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310401 · Cited by 72
The use of nanotechnology to combat liver cancer: Progress and perspectives
Mintz, K. J., & Leblanc, R. M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188621 · Cited by 71
Huang, J., & Xiao, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081586 · Cited by 73
“Recently, Liu shuai’s group synthesized a series of novel multi-tailed ionizable phospholipids (iPhos) to form multi-component lipid nanoparticles (iPLNPs) for organ-selective nuclei acid delivery [59].”
BackgroundLipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application
Mashima, R., & Takada, S. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100341 · Cited by 73
“5 Not added [69] 5A2-SC8/DOPE/Chol/C14PEG2000 = 23.”
BackgroundInfluentialIonizable Lipid Nanoparticles for mRNA Delivery
Tang, X., Zhang, Y., & Han, X. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300006 · Cited by 76
Harnessing lipid nanoparticles for efficient CRISPR delivery
Yan, J., Kang, D. D., & Dong, Y. (2021) · Biomaterials Science · doi:10.1039/d1bm00537e · Cited by 69
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B., Sauvage, F., Guagliardo, R., Muntean, C., Nguyen, V. P., Pottie, E., Wels, M., Minnaert, A., Rycke, R. M. D., Yang, Q., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.009 · Cited by 69
Dirisala, A., Uchida, S., Li, J., Guyse, J. F. R. V., Hayashi, K., Vummaleti, S. V. C., Kaur, S., Mochida, Y., Fukushima, S., & Kataoka, K. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202100754 · Cited by 67
Padilla, M. S., Mrksich, K., Wang, Y., Haley, R. M., Li, J. J., Han, E. L., El-Mayta, R. D., Kim, E. H., Dias, S., Gong, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55137-6 · Cited by 74
“To verify this, we studied the interactions of the eight LNPs with 200-core ILs with arti fi cial endosomes, a previously validated strategy to study the role of endosomal escape 50,51 .”
Structure and Morphology of Lipid Nanoparticles for Nucleic Acid Drug Delivery: A Review
Udepurkar, A. P., Devos, C., Sagmeister, P., Destro, F., Inguva, P., Ahmadi, S., Boulais, É., Quan, Y., Braatz, R. D., & Myerson, A. S. (2025) · ACS Nano · doi:10.1021/acsnano.4c18274 · Cited by 74
Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy
Hao, Y., Ji, Z., Zhou, H., Wu, D., Gu, Z., Wang, D., & ten Dijke, P. (2023) · MedComm · doi:10.1002/mco2.339 · Cited by 71
CRISPR Spherical Nucleic Acids
Huang, C., Han, Z., Evangelopoulos, M., & Mirkin, C. A. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07913 · Cited by 67
Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
Yi, K., Kong, H., Lao, Y., Li, D., Mintz, R. L., Fang, T., Chen, G., Tao, Y., Li, M., & Ding, J. (2023) · Advanced Materials · doi:10.1002/adma.202300665 · Cited by 66
Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics
Vasileva, O., Zaborova, O. V., Shmykov, B., Ivanov, R. A., & Reshetnikov, V. V. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1466337 · Cited by 72
“Researchers have done a lot of work on the synthesis of new zwitterionic phospholipids (Liu et al., 2021).”
BackgroundInfluentialFeng, Y., Tai, W., Huang, P., Qi, S., Yu, X., Li, M., Li, M., Zhang, M., Cao, F., Gao, X., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02284-w · Cited by 70
“Researchers have focused on developing various ionizable and cationic lipids 21,22 , yet challenges remain in creating delivery systems with high efficacy and low hepatotoxicity.”
Self-citationForster, J., Nandi, D., & Kulkarni, A. A. (2022) · Biomaterials Science · doi:10.1039/d2bm00883a · Cited by 66
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
Matarazzo, L., & Bettencourt, P. J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172691 · Cited by 68
Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length
Mrksich, K., Padilla, M. S., Joseph, R. A., Han, E. L., Kim, D., Palanki, R., Xu, J., & Mitchell, M. J. (2024) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37705 · Cited by 67
“36,37 Moreover, certain IL structures enhance the immunogenicity of mRNA LNP vaccines, further demonstrating their clinical relevance.”
BackgroundmRNA therapies: Pioneering a new era in rare genetic disease treatment
Shen, G., Liu, J., Yang, H., Xie, N., & Yang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.056 · Cited by 62
Tissue-specific mRNA delivery and prime editing with peptide–ionizable lipid nanoparticles
Lin, Y., Li, M., Luo, Z., Meng, Y., Zong, Y., Ren, H., Yu, X., Tan, X., Liu, F., Wei, T., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02320-9 · Cited by 87
“No statistical methods were used to predetermine the sample sizes, but our sample sizes are similar to those reported in previous publications 25,44 .”
Self-citationLi, Z., Zhang, X., Ho, W., Bai, X., Jaijyan, D. K., Li, F., Kumar, R., Kolloli, A., Subbian, S., Zhu, H., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204462 · Cited by 62
RNA modification in mRNA cancer vaccines
Mei, Y., & Wang, X. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01020-5 · Cited by 62
Mehta, M. J., Kim, H. J., Lim, S. B., Naito, M., & Miyata, K. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202300366 · Cited by 61
Li, Y., Li, X., Wei, L.-S., & Ye, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1451989 · Cited by 63
The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system
Jiang, X., Zhang, T., & Gao, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114324 · Cited by 61
Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma
Xu, M., Liu, Y., Lin, Y., Lu, Y., Bi, X., Jiang, T., Deng, W., Zhang, L., Yi, W., Xie, Y., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01615-2 · Cited by 62
“In 2021, Professor Siegwart’s team [147] developed an organ-selective targeting (SORT) technology.”
BackgroundThe CRISPR/Cas9 System Delivered by Extracellular Vesicles
Zhu, X., Gao, M., Yang, Y., Li, W., Bao, J., & Li, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030984 · Cited by 61
“chemical and biological obstacles and the immune system [10,23].”
BackgroundYuan, Z., Yan, R., Fu, Z., Wu, T., & Ren, C. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.172240 · Cited by 61
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 62
Self-citationCRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Alsaiari, S. K., Eshaghi, B., Du, B., Kanelli, M., Li, G., Wu, X., Zhang, L., Chaddah, M., Lau, A., Yang, X., et al. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00725-7 · Cited by 63
“To enable the tissue-selective delivery of Cas9 mRNA and sgRNA to the spleen, liver and lungs, multi-component LNPs were formulated from membrane-destabilizing ionizable phospholipids 131 .”
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 61
“Adapted with permission from [31], copyright 2021, Springer Nature.”
Self-citationApplication of lipid-based nanoparticles in cancer immunotherapy
Zhang, Z., Yao, S., Hu, Y., Zhao, X. B., & Lee, R. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967505 · Cited by 58
Dynamic carriers for therapeutic RNA delivery
Berger, S., Lächelt, U., & Wagner, E. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307799120 · Cited by 61
Foley, R. A., Sims, R. A., Duggan, E. C., Olmedo, J. K., Ma, R., & Jonas, S. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.973326 · Cited by 60
“In addition, straightforward lipid selfassembly may be leveraged to be scalable and their modular composition has enabled some amenability to targeting specific tissues, even via systemic administration (Liu et al., 2021).”
BackgroundBranched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy
Yan, Y., Liu, X., Wang, L., Wu, C., Shuai, Q., Zhang, Y., & Liu, S. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122279 · Cited by 56
Self-citationThiophene-based lipids for mRNA delivery to pulmonary and retinal tissues
Eygeris, Y., Gupta, M., Kim, J., Jozić, A., Gautam, M., Renner, J., Nelson, D., Bloom, E., Tuttle, A., Stoddard, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307813120 · Cited by 58
“Previously, tropism to these specific organs in case of SORT - lipids was attributed to cationic and anionic charge, respectively (3, 14).”
BackgroundZhang, Z., Ma, B., Li, B., Li, Z., Gao, M., Zhao, H., Peng, R., Hu, J., Wang, Y., You, W., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102209 · Cited by 59
Intelligent nanotherapeutic strategies for the delivery of CRISPR system
Chen, C., Zhong, W., Du, S., Li, Y., Zeng, Y., Liu, K., Yang, J., Guan, X., & Han, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.013 · Cited by 56
Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components
Wu, F., Li, N., Xiao, Y., Palanki, R., Yamagata, H. M., Mitchell, M. J., & Han, X. (2025) · Small Methods · doi:10.1002/smtd.202401632 · Cited by 64
Surface engineering of nanoparticles for precision medicine
Zheng, J., Sun, Y., Shen, Y., & Zhou, Z. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100037 · Cited by 55
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
Proton‐Driven Transformable 1O2‐Nanotrap for Dark and Hypoxia Tolerant Photodynamic Therapy
Chen, D., Dai, H., Wang, W., Cai, Y., Mou, X., Zou, J., Shao, J., Mao, Z., Zhong, L., Dong, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202200128 · Cited by 55
Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma
Liu, Y., Zhang, D., An, Y., Sun, Y., Li, J., Zheng, M., Zou, Y., & Shi, B. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101790 · Cited by 52
Zhou, Q., Liu, Q., Wang, Y., Chen, J., Schmid, O., Rehberg, M., & Yang, L. (2024) · Advanced Science · doi:10.1002/advs.202308659 · Cited by 51
Pegoraro, C., Domingo-Ortí, I., Conejos‐Sánchez, I., & Vicent, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115195 · Cited by 56
Modern therapeutic approaches to liver-related disorders
Gardin, A., Remih, K., Gonzales, E. M., Andersson, E. R., & Strnad, P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.015 · Cited by 51
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Zeng, S., Chen, Y., Zhou, F., Zhang, T., Fan, X., Chrzanowski, W., Gillies, M. C., & Zhu, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114965 · Cited by 51
Enhancing CRISPR/Cas systems with nanotechnology
Chowdhry, R., Lu, S. Z., Lee, S., Godhulayyagari, S., Ebrahimi, S. B., & Samanta, D. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.06.005 · Cited by 50
A Unified Strategy to Improve Lipid Nanoparticle Mediated mRNA Delivery Using Adenosine Triphosphate
Ma, Y., & Fenton, O. S. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05574 · Cited by 52
Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy
Godbout, K., & Tremblay, J. P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102129 · Cited by 51
“Liu 2021 [101] Cre mRNA Lungs IV 9A1P9 46 Transfection of ~34% of all endothelial cells, ~20% of all epithelial cells, and ~13% of immune cells DDAB 23”
BackgroundCellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
Steering the course of CAR T cell therapy with lipid nanoparticles
Khawar, M. B., Afzal, A., Si, Y., & Sun, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02630-1 · Cited by 54
Omo‐Lamai, S., Wang, Y., Patel, M. N., Essien, E., Shen, M., Majumdar, A., Espy, C. L., Wu, J., Channer, B., Tobin, M. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.16.589801 · Cited by 48
“Once protonated in the acidic endosome, ionizable lipids form ion pairs with the anionic lipids in the endosomal membrane, leading to the formation of an inverse hexagonal phase that disrupts the endosomal membrane and releases the RNA cargo into the cytosol 31–33 .”
Genome editing in large animal models
Maynard, L. H., Humbert, O., Peterson, C. W., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.026 · Cited by 50
TGF-βR2 signaling coordinates pulmonary vascular repair after viral injury in mice and human tissue
Zhao, G., Xue, L., Weiner, A. I., Gong, N., Adams‐Tzivelekidis, S., Wong, J., Gentile, M. E., Nottingham, A. N., Basil, M. C., Lin, S. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg6229 · Cited by 49
Synthetic Biology‐Based Engineering Cells for Drug Delivery
Yi, W., Hu, S., Qian, X., Yan, W., & Li, Y. (2025) · Exploration · doi:10.1002/exp.20240095 · Cited by 49
More than a delivery system: the evolving role of lipid-based nanoparticles
Karmaker, S., Rosales, P. D., Tirumuruhan, B., Viravalli, A., & Boehnke, N. (2025) · Nanoscale · doi:10.1039/d4nr04508d · Cited by 56
Lu, Z., & Sun, D. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03890-8 · Cited by 53
“…tails have been designed to overcome the limitations of lamellar ionizable lipids and enhance cytosolic nucleic acid delivery efficiency [15, 22, 25, 62, 68–71]. pH-dependent hemolytic assays have also demonstrated that the LNPs of some of these ionizable lipids exhibit effective…”
Microfluidic Platform Enables Shearless Aerosolization of Lipid Nanoparticles for mRNA Inhalation
Kim, J., Jozić, A., Bloom, E., Jones, B., Marra, M., Murthy, N. T. V., Eygeris, Y., & Sahay, G. (2024) · ACS Nano · doi:10.1021/acsnano.4c00768 · Cited by 52
van Hees, M., Slott, S., Hansen, A. H., Kim, H. S., Ji, H. P., & Astakhova, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.003 · Cited by 47
Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Steffens, R. C., & Wagner, E. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03385-w · Cited by 48
“Based on these observations, methods which enable fast screening of broad libraries of nucleic acid carriers in vivo were developed [106-109].”
BackgroundMethodOn the mechanism of tissue-selective gene delivery by lipid nanoparticles
Kimura, S., & Harashima, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.052 · Cited by 46
Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers
Ouyang, X., Liu, Y., Zheng, K., Pang, Z., & Peng, S. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100883 · Cited by 47
“10 A) [161] .”
Chen, Z., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14500 · Cited by 46
Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy
Aziz, A., Rehman, U., Sheikh, A., Abourehab, M. A. S., & Kesharwani, P. (2022) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2022.2121592 · Cited by 47
Engineered multi-domain lipid nanoparticles for targeted delivery
Liu, Z., Chen, J., Xu, M., Ho, S., Wei, Y., Ho, H., & Yong, K. (2025) · Chemical Society Reviews · doi:10.1039/d4cs00891j · Cited by 63
Peptide codes for organ-selective mRNA delivery
Chang, T., Zheng, Y., Jiang, M., Jia, S., Bai, J., Zheng, Z., Li, S., Guo, J., Wang, Y., Wang, Y., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02331-6 · Cited by 59
“No statistical methods were used to predetermine the https://doi.org/10.1038/s41563-025-02331-6 sample sizes, but our sample sizes are similar to those reported in previous publications 11,15,59 .”
InfluentialSelf-citationMa, Y., & Fenton, O. S. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c02584 · Cited by 44
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders
Chu, R., Wang, Y., Kong, J., Pan, T. S., Yang, Y., & He, J. F. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02766j · Cited by 49
Eftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 46
“53 However, concerns regarding their toxicity, especially those composed of polycationic and pegylated lipids, have been raised in several studies.”
BackgroundDevelopment of Thermally Stable mRNA-LNP Delivery Systems: Current Progress and Future Prospects
Kafle, U., Truong, H. Q., Cao, T. G. N., & Meng, F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00826 · Cited by 47
Kumar, G., & Ardekani, A. M. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01716 · Cited by 48
Advanced nano-based strategies for mRNA tumor vaccine
Qu, Y., Xu, J., Zhang, T., Chen, Q., Sun, T., & Jiang, C. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.025 · Cited by 42
“Here listed targeting ligand include triMN 49 , imidazole group 55 , and phosphpserine 51 ; phospholipids include iPhos 68 , DOPE 68 , stearic acid 48 , 14 PA 54 , 18BMP 54 ; ionizable lipids include CL4F m-n 64 , charge-altering releasable transporters (CARTs) 67 , 113-O12B 62 , 4N4T with…”
BackgroundInfluentialCarbonate-Bearing Ionizable Lipids for mRNA Delivery to Splenic NK Cells
Wu, S., Shi, L., Su, K., Lin, L., Yan, X., Zhang, Y., Gu, T., Wang, Z., Xu, T., & Liu, S. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c01389 · Cited by 44
Self-citationOu, L., Chen, H., Yuan, B., & Yang, K. (2022) · ACS Nano · doi:10.1021/acsnano.2c04774 · Cited by 42
Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Zhao, Y., Gan, L., Ke, D., Chen, Q., & Fu, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04553-1 · Cited by 45
Li, Z., Amaya, L., Ee, A., Wang, S. K., Ranjan, A., Waymouth, R. M., Chang, H. Y., & Wender, P. A. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c02704 · Cited by 41
Selective organ targeting nanoparticles: from design to clinical translation
Li, J., & Wang, H. (2023) · Nanoscale Horizons · doi:10.1039/d3nh00145h · Cited by 42
Xue, L., Xiong, X., Zhao, G., Arocho, W. A. M., Palanki, R., Xiao, Z., Han, X., Yoon, I., Figueroa‐Espada, C. G., Xu, J., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10265 · Cited by 41
The potential of mRNA vaccines in cancer nanomedicine and immunotherapy
Pan, S., Fan, R., Han, B. R., Tong, A., & Guo, G. F. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.11.003 · Cited by 39
Towards design of drugs and delivery systems with the Martini coarse-grained model
Kjølbye, L. R., Pereira, G. P., Bartocci, A., Pannuzzo, M., Albani, S., Marchetto, A., Jiménez‐García, B., Martin, J., Rossetti, G., Cecchini, M., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16 · Cited by 42
“Cell specific LNPs can be built by changing one or more of the lipid components (Liu et al ., 2021; Ż ak and Zangi, 2021), but models of synthetic lipids are not always available.”
BackgroundHuang, X., Li, A., Xu, P., Yu, Y., Li, S., Hu, L., & Feng, S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01952-w · Cited by 43
Alshehry, Y., Liu, X., Zhang, Y., & Zhu, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113617 · Cited by 39
Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles
Lee, D. S., Amirthalingam, S., Lee, C., Rajendran, A. K., Ahn, Y.-H., & Hwang, N. S.-Y. (2023) · Nanoscale Advances · doi:10.1039/d3na00198a · Cited by 40
Yan, J., Zhang, H., Li, G., Su, J., Wei, Y., & Xu, C. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.10.012 · Cited by 40
Nano-vectors for CRISPR/Cas9-mediated genome editing
Yang, P., Lee, A. Y.-T., Xue, J., Chou, S., Lee, C., Tseng, P., Zhang, T. X., Zhu, Y., Lee, J., Chiou, S., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101482 · Cited by 41
Metadata
- Authors
- Liu, S., Cheng, Q., Wei, T., Yu, X., Johnson, L. T., Farbiak, L., & Siegwart, D. J.
- Affiliations
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Siegwart, Daniel J.
- Venue
- Nature Materials
- Published
- 2021-02-04
- Volume
- 20
- Issue
- 5
- Pages
- 701-710
- ISSN
- 1476-1122 (ISSN-L)
- 1476-4660
- PMC
- PMC8188687
- OpenAlex
- W3127944141
- Cited by
- 653
- References
- 54
- Citations by year
- 2026: 107 · 2025: 154 · 2024: 139 · 2023: 122 · 2022: 90 · 2021: 40
- FWCI
- 30.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Materials (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RP160157)
- U.S. Department of Health & Human Services | National Institutes of Health (R01 EB025192-01A1)
- American Cancer Society (RSG-17-012-01)
- Welch Foundation (I-1855)
- Cystic Fibrosis Foundation (SIEGWA18XX0)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (5P30CA142543)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- endosomal escape, mRNA delivery, CRISPR/Cas9 genome editing, lipid nanoparticles, zwitterionic lipids, membrane perturbation, structure-activity relationship, helper lipids, nucleic acid therapeutics
- MeSH terms
- Gene Editing, Animals, Cell Line, Cell Membrane, Female, Organ Specificity, Phospholipids, RNA, Messenger, Drug Delivery Systems, Mice, Administration, Intravenous, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
